Akebia Therapeutics Inc. AKBA

NAS: AKBA | ISIN: US00972D1054   26/07/2024
1,440 USD (-2,70%)
(-2,70%)   26/07/2024

11 juli 2024 · Akebia Therapeutics Provides Update on Continued Momentum of Commercial Launch of Vafseo® (vadadustat) Tablets · Persbericht

1 juli 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

27 juni 2024 · Akebia Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference · Persbericht

24 juni 2024 · Akebia Therapeutics Appoints Erik Ostrowski as Chief Financial Officer and Chief Business Officer · Persbericht

3 juni 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

23 mei 2024 · Akebia Therapeutics to Present at the Jefferies Global Healthcare Conference · Persbericht

14 mei 2024 · Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference · Persbericht

9 mei 2024 · Akebia Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights · Persbericht

2 mei 2024 · Akebia Therapeutics to Report First Quarter 2024 Financial Results and Discuss Recent Business Highlights · Persbericht

1 mei 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

2 april 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

28 maart 2024 · Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis · Persbericht

14 maart 2024 · Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights · Persbericht

11 maart 2024 · Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results · Persbericht

1 maart 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

2 februari 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

30 januari 2024 · Akebia Secures $55 Million Term Loan Financing · Persbericht

9 januari 2024 · Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer · Persbericht

2 januari 2024 · Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) · Persbericht

20 december 2023 · Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference · Persbericht

Mijn selecties